Bio-Rad Laboratories Expands Their EQAS Offering with Three New Programs


HERCULES, CA – January 11, 2013 — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a multinational manufacturer and distributor of life science research and clinical diagnostics products, announces the release of three External Quality Assurance Service (EQAS®) Programs for clinical laboratories and near patient/POC settings around the world. The new programs are: Cardiac Markers, Ethanol/Ammonia, and Lipids.

All three of the programs are designed for the quantitative measurement of important markers for assessing cardiac health and risk of failure, normal to abnormal (or toxic) ranges for Ethanol and Ammonia in serum, and a full range of lipid profile testing in the clinical chemistry laboratory, respectively.

The programs are set up so that one of 12 plasma/serum samples is tested each month throughout a one-year cycle. Test results are included in a monthly report that is either posted online or mailed directly to participants. The report includes informative statistical analyses and valuable peer group comparisons. A comprehensive End-of-Cycle Report provides an overall assessment of bias over the entire cycle. Registered EQAS participants may access their reports online at QCNet™ (

As a provider of proficiency testing (PT) programs, Bio-Rad offers fully accredited PT/EQA programs in chemistry (serum and urine), immunoassay, therapeutic drugs, hemoglobin, and hematology.

For more information, please call 1-800-224-6723 or visit

About Bio-Rad 
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) has remained at the center of scientific discovery for 60 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 100,000 research and industry customers worldwide through its global network of operations. The company employs over 7,100 people globally and had revenues exceeding $2 billion in 2011. For more information, visit

This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, “believe,” “expect,” “may,” “will,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the “Risk Factors” in the Company’s public reports filed with the Securities and Exchange Commission, including the Company’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements.

For more information contact:
Azita Mokhtari, Product Manager
Bio-Rad Laboratories, Inc.